NO167203C - Analogifremgangsmaate for fremstilling av terapeutisk aktive piperazinyl-derivater av puriner. - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive piperazinyl-derivater av puriner.

Info

Publication number
NO167203C
NO167203C NO883204A NO883204A NO167203C NO 167203 C NO167203 C NO 167203C NO 883204 A NO883204 A NO 883204A NO 883204 A NO883204 A NO 883204A NO 167203 C NO167203 C NO 167203C
Authority
NO
Norway
Prior art keywords
preparation
purines
therapeutic active
analogy procedure
piperazinyl derivatives
Prior art date
Application number
NO883204A
Other languages
English (en)
Norwegian (no)
Other versions
NO167203B (no
NO883204D0 (no
NO883204L (no
Inventor
David B R Johnston
Stephen Marburg
Richard L Tolman
Malcolm Maccoss
Laura C Meurer
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO883204D0 publication Critical patent/NO883204D0/no
Publication of NO883204L publication Critical patent/NO883204L/no
Publication of NO167203B publication Critical patent/NO167203B/no
Publication of NO167203C publication Critical patent/NO167203C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/40Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
NO883204A 1987-07-20 1988-07-19 Analogifremgangsmaate for fremstilling av terapeutisk aktive piperazinyl-derivater av puriner. NO167203C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7536287A 1987-07-20 1987-07-20

Publications (4)

Publication Number Publication Date
NO883204D0 NO883204D0 (no) 1988-07-19
NO883204L NO883204L (no) 1989-01-23
NO167203B NO167203B (no) 1991-07-08
NO167203C true NO167203C (no) 1991-10-16

Family

ID=22125206

Family Applications (1)

Application Number Title Priority Date Filing Date
NO883204A NO167203C (no) 1987-07-20 1988-07-19 Analogifremgangsmaate for fremstilling av terapeutisk aktive piperazinyl-derivater av puriner.

Country Status (17)

Country Link
EP (1) EP0300726B1 (fr)
JP (1) JP2562181B2 (fr)
KR (1) KR890002155A (fr)
AT (1) ATE94877T1 (fr)
AU (1) AU601862B2 (fr)
CA (1) CA1341043C (fr)
DE (1) DE3884304T2 (fr)
DK (1) DK403188A (fr)
ES (1) ES2058291T3 (fr)
FI (1) FI883423A (fr)
HU (1) HU199144B (fr)
IL (1) IL87149A (fr)
NO (1) NO167203C (fr)
NZ (1) NZ225447A (fr)
PT (1) PT88029B (fr)
YU (1) YU46761B (fr)
ZA (1) ZA885242B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86007A0 (en) * 1987-04-09 1988-09-30 Wellcome Found 6-substituted purine nucleosides,their preparation and pharmaceutical compositions containing them
GB8716313D0 (en) * 1987-07-10 1987-08-19 Janssen Pharmaceutica Nv 2-(heterocyclylalkyl)imidazopyridines
GB8922076D0 (en) * 1989-09-28 1989-11-15 Beecham Group Plc Novel process
DK150591D0 (da) * 1991-08-26 1991-08-26 Novo Nordisk As Kemisk forbindelse
US5583137A (en) * 1992-02-19 1996-12-10 Pfizer Inc. Heterocyclic compounds for enhancing antitumor activity
US5864037A (en) * 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
AU3053999A (en) 1998-03-31 1999-10-25 Kyowa Hakko Kogyo Co. Ltd. Nitrogenous heterocyclic compounds
AU2003222786A1 (en) * 2002-04-18 2003-10-27 Ucb, S.A. Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
CN100376573C (zh) 2002-12-04 2008-03-26 卫材R&D管理有限公司 稠合的1,3-二氢-咪唑环化合物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
MXPA06002521A (es) 2003-09-05 2006-06-20 Altana Pharma Ag Uso de inhibidores de pde4 para el tratamiento de diabetes mellitus.
ES2381890T3 (es) 2003-12-22 2012-06-01 K.U.Leuven Research & Development Compuesto de imidazo[4,5-c]piridina y métodos de tratamiento antiviral
RU2007101509A (ru) 2004-06-17 2008-07-27 Уайт (Us) Способ получения антагонистов рецепторов гормона, высвобождающего гонадотропин
MXPA06014798A (es) 2004-06-17 2007-06-22 Wyeth Corp Antagonistas del receptor de hormona para liberar gonadotropina.
JP2008524335A (ja) 2004-12-21 2008-07-10 ギリアド サイエンシズ, インコーポレイテッド イミダゾ[4,5−c]ピリジン化合物および抗ウイルス処置法
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
NZ560269A (en) 2005-03-08 2010-12-24 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
ATE454384T1 (de) 2006-07-07 2010-01-15 Gilead Sciences Inc Neue pyridazinverbindung und ihre verwendung
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
CN102089308A (zh) * 2008-07-07 2011-06-08 艾科睿控股公司 Pi3k亚型选择性抑制剂
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
JP5647998B2 (ja) * 2009-03-13 2015-01-07 カトリーケ ユニバーシテイト ルーヴェン、ケー.ユー. ルーヴェン アール アンド ディー 免疫抑制剤としてのチアゾロピリミジン調節因子
ES2481867T3 (es) 2010-03-31 2014-07-31 Eli Lilly And Company Compuestos de purina usados como agonistas de CB2
AR080711A1 (es) 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012118972A2 (fr) 2011-03-01 2012-09-07 Synegy Pharmaceuticals Inc. Procédé de préparation d'agonistes du guanylate cyclase c
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
ES2680935T3 (es) * 2013-05-02 2018-09-11 F. Hoffmann-La Roche Ag Derivados de purina como agonistas del receptor CB2
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
CN105979959B (zh) 2013-08-09 2021-11-30 阿德利克斯公司 用于抑制磷酸盐转运的化合物和方法
CN104497085B (zh) * 2015-01-16 2017-05-24 华东理工大学 腺苷衍生物及其用途
WO2020237096A1 (fr) 2019-05-21 2020-11-26 Ardelyx, Inc. Combinaison pour baisser le phosphate sérique chez un patient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1115260B (de) * 1957-02-27 1961-10-19 Thomae Gmbh Dr K Verfahren zur Herstellung von Purinderivaten
GB1186504A (en) * 1966-10-15 1970-04-02 Fisons Pest Control Ltd Substituted Heterocyclic Compounds
JPS60260579A (ja) * 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
JPS6210085A (ja) * 1985-07-05 1987-01-19 Yoshitomi Pharmaceut Ind Ltd トリフルオロメチルプリン誘導体

Also Published As

Publication number Publication date
ATE94877T1 (de) 1993-10-15
AU1923088A (en) 1989-01-27
NO167203B (no) 1991-07-08
HUT47575A (en) 1989-03-28
PT88029A (pt) 1989-06-30
IL87149A (en) 1994-05-30
NO883204D0 (no) 1988-07-19
ZA885242B (en) 1989-03-29
PT88029B (pt) 1995-03-01
AU601862B2 (en) 1990-09-20
NZ225447A (en) 1991-12-23
HU199144B (en) 1990-01-29
FI883423A0 (fi) 1988-07-19
DE3884304D1 (de) 1993-10-28
JPH01104074A (ja) 1989-04-21
NO883204L (no) 1989-01-23
YU46761B (sh) 1994-05-10
KR890002155A (ko) 1989-04-08
EP0300726B1 (fr) 1993-09-22
ES2058291T3 (es) 1994-11-01
CA1341043C (fr) 2000-07-04
IL87149A0 (en) 1988-12-30
EP0300726A1 (fr) 1989-01-25
DK403188D0 (da) 1988-07-19
YU141088A (en) 1990-10-31
DE3884304T2 (de) 1994-03-24
FI883423A (fi) 1989-01-21
JP2562181B2 (ja) 1996-12-11
DK403188A (da) 1989-03-30

Similar Documents

Publication Publication Date Title
NO167203C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive piperazinyl-derivater av puriner.
DE3466227D1 (en) Insulin derivatives, processes for their preparation, their use and pharmaceutical compositions for the treatment of diabetes mellitus
HUP0002373A2 (hu) Glükagon antagonisták/inverz agonisták és ezeket tartalmazó gyógyászati készítmények
NO171365C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
MY102016A (en) Thiazolidinedione derivatives, their production and use.
DK642587D0 (da) Insulinpraeparat
NO890259D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive etylfenoksyacetamider.
IT1226727B (it) Farmaci precursori della dopamina.
DE68924006D1 (de) Pharmazeutische Zusammensetzungen mit Eierschalenbestandteilen und ihre Herstellung und Verwendung.
NO172043C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-2,3-butadienyl-triamioalkanderivater
IE890580L (en) Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants
DE3586993D1 (de) Kontinuierliche intravenoese infusion von adenosin an menschlichen patienten, einheitsdosierungsform von adenosin und dessen verwendung bei der herstellung von arzneimitteln.
NO893256D0 (no) Fremgangsmaate for fremstilling av furyltiazolderivater.
HUT46214A (en) Process for producing medical preparation suitable for treatment of peptic ulcer
EP0324520A3 (fr) Alkyl-pipérazinyl-5,6-alkylènepyrimidines
KR890001555A (ko) 요산 배설용 조성물
DK417889D0 (da) Anvendelse af 2-azabicyklo(2.2.2.)-carboxylsyrederivater til fremstilling af medicinske produkter til behandling af vaskulaere sygdomme
ATE84418T1 (de) 2,6-diamino-3-phenyl-azo-pyridin enthaltendes tier- und humanarzneimittel mit antiviraler und antitumoraler aktivitaet.
González Drug treatment and nutrient therapy: The distinction blurs.
NO881798D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.